Fund managers believe that the regulatory advisory on smallcap funds will not have an impact on the broader markets but will improve transparency in the mutual fund space. However, they suggest that investors be cautious in this space as valuations… और पढ़ें »Will SEBI advisory impact investing strategy of smallcap funds?
The complaint accuses Dr Reddy#39;s of improperly restraining competition and maintaining a monopoly in the sale of the cancer drug Revlimid Read More The complaint accuses Dr Reddy#39;s of improperly restraining competition and maintaining a monopoly in the sale of… और पढ़ें »Dr Reddy#39;s drops 4% after being named in US anti-trust lawsuit
R K Swamy IPO : The price band for the issue has been fixed at Rs 270-288 per share. Read More R K Swamy IPO : The price band for the issue has been fixed at Rs 270-288 per share.… और पढ़ें »RK Swamy IPO: 10 things to know before subscribing to the Rs 423-crore issue
The biggest Nifty gainers were Tata Steel, LT, JSW Steel, Titan Company and IndusInd Bank, while losers were Dr Reddy#39;s Laboratories, Sun Pharma, HCL Technologies, Infosys and Britannia Industries Read More The biggest Nifty gainers were Tata Steel, LT, JSW… और पढ़ें »Taking Stock: Sensex, Nifty at a new high on blowout GDP data, Nifty Bank reclaims 47,000
Among sectors, the metal index closed 4 percent higher, while auto, bank, capital good and oil gas were up 2 percent each Read More Among sectors, the metal index closed 4 percent higher, while auto, bank, capital good and oil… और पढ़ें »Gainers and Losers: 10 stocks that moved the most on March 1
For the market to move higher, banking names have to participate in the rally, say experts Read More For the market to move higher, banking names have to participate in the rally, say experts For the market to move higher,… और पढ़ें »Banking stocks propel Sensex, Nifty to new highs but analysts warn of stretched valuations
Indian generic companies have benefited from the continuing shortages and approval slowdown in the US. Read More Indian generic companies have benefited from the continuing shortages and approval slowdown in the US. Indian generic companies have benefited from the continuing… और पढ़ें »Strong India growth, benign price erosion in the US drive Q3 earnings for Indian pharma
NULL Read More NULL NULL Moneycontrol Latest News Read More NULL
NULL Read More NULL NULL Moneycontrol Latest News Read More NULL
NULL Read More NULL NULL Moneycontrol Latest News Read More NULL
हिन्दी 
English